NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Metrics to compare | NEXI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNEXIPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −4.0x | −0.7x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 1.8x | 2.6x | |
Price / LTM Sales | 0.0x | 9.4x | 3.4x | |
Upside (Analyst Target) | 0.0% | 128.7% | 37.8% | |
Fair Value Upside | Unlock | 5.3% | 5.5% | Unlock |